Activation ratio of MMP-2 and expression of MT1-MMP are correlated in thymic epithelial tumours

Pathology

Volumn 39, Issue 5, 2007, Pages 486-490

  Wang, Yan ^a   Xu, Hong Tao ^a   Ueda, Yoshimichi ^b   Shimasaki, Miyako ^b   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Invasion; Matrix metalloproteinases; Metastasis; Thymoma

Indexed keywords

AZELASTINE; GELATIN; GELATINASE A; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; EPITHELIUM TUMOR; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LYMPHOCYTE; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; STROMA CELL; THYMOMA; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LASERS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MICRODISSECTION; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMUS NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 34548832806     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701569964     Document Type: Article

References (21)

1. Shimosato Y, Mukai K. Atlas of Tumor Pathology. Tumors of the Mediastinum. 3rd Series, Fascicle 21, Washington DC: Armed Forces Institute of Pathology, 1997; 40-120.
2. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004; 152-66.
3. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94: 624-32.
4. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002; 95: 420-9.
5. Yoshizaki T, Maruyama Y, Sato H, et al. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 2001; 95: 44-50.
6. Tsukifuji R, Tagawa K, Hatamochi A, et al. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis. Br J Cancer 1999; 80: 1087-91.
7. Wagner SN, Ockenfels HM, Wagner C, et al. Differential expression of tissue inhibitor of metalloproteinase-2 by cutaneous squamous and basal cell carcinomas. J Invest Dermatol 1996; 106: 321-6.
8. Yamashita K, Mori M, Kataoka A, et al. The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 2001; 84: 276-82.
9. Kuo TT, Lo SK. DNA flow cytometric study of thymic epithelial tumors with evaluation of its usefulness in the pathologic classification. Hum Pathol 1993; 24: 746-9.
10. Kondo K, Kinoshita H, Ishikura H, et al. Activation of matrix metalloproteinase-2 is correlated with invasiveness in thymic epithelial tumors. J Surg Oncol 2001; 76: 169-75.
11. Sasaki H, Yukiue H, Kobayashi Y, et al. Elevated serum pro-MMP2 levels in patients with stage IV thymoma. Surg Today 2002; 32: 482-6.
12. Yukiue H, Sasaki Y, Kobayashi Y, et al. Clinical significance of tissue inhibitor of metalloproteinases and matrix metalloproteinases mRNA expression in thymoma. J Surg Res 2003; 109: 86-91.
13. Sogawa K, Kondo K, Fujino H, et al. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors. Cancer 2003; 98: 1822-9.
14. Takahashi E, Tateyama H, Akatsu H, et al. Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the world health organization classification subtype and clinical stage of thymic epithelial tumors. Hum Pathol 2003; 34: 1253-8.
15. Kirchner T, Schalke B, Buchwald J, et al. Well-differentiated thymic carcinoma. An organotypical low-grade carcinoma with relationship to cortical thymoma. Am J Surg Pathol 1992; 16: 1153-69.
16. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-8.
17. Ikeda M, Maekawa R, Tanaka H, et al. Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in Situ zymography. Clin Cancer Res. 6, 3290-6.
18. Imai K, Ohuchi E, Aoki T, et al. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 1996; 56: 2707-10.
19. Pajouh MS, Nagle RB, Breathnach R, et al. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 1991; 117: 144-50.
20. Nakagawa H, Yagihashi S. Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung. Jpn J Cancer Res 1994; 85: 934-8.
21. Davies B, Miles DW, Happerfield LC, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126-31.